Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Readout of the delayed Galaxies Lung-201 study is due imminently.
The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.
Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.
Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.
After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.
First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.